TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03106025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmology Assessment
Description: Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmology Assessment
Description: Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
Study: NCT03661190

Intervention type: OTHER
Group type: OTHER
Intervention: Grammatical Reasoning
Description: START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.

Intervention type: OTHER
Group type: OTHER
Intervention: Card Pairs
Description: A basic picture-matching task.
Study: NCT00715923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified consent form
Description: modified consent form used

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard consent form
Description: standard consent form used
Study: NCT04408131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: virological test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: serological test
Study: NCT01268891

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily; tablet; orally; 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect®
Description: 1 mg daily; tablet; orally; 18 weeks
Study: NCT01164683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Description: Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
Study: NCT03530800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 10 weeks
Study: NCT01924624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
Study: NCT02589379

Intervention type: PROCEDURE
Intervention: Pancreatic Resection
Description: Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
Study: NCT01157234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of \< 140/ 90.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure \< 140/90.
Study: NCT04083534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5459
Description: Administered by intravenous (IV) infusion
Study: NCT02120612

Intervention type: OTHER
Intervention: Naloxone Education Intervention
Description: The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders.
Study: NCT02034032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenexx SD
Description: stem cell treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: exercise therapy control
Study: NCT00973674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin IV
Description: One time dose of Premarin IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time dose of Placebo
Study: NCT03521427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive bimanual therapy
Description: Ninety hours of intensive bimanual therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive neurodevelopmental therapy
Description: Ninety hours of intensive neurodevelopmental therapy
Study: NCT04619459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Description: Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
Study: NCT00815399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15-45 mg/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500-2000 mg/die
Study: NCT00549874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: oral 8 mg/once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 20 mg/ once daily for 6 months
Study: NCT02553382

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary, Herbal
Description: Viscous fibre blend and Salba and American and Korean Red Ginseng capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Positive Control
Description: Oat bran blend and wheat bran capsules
Study: NCT05352373

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sodium bicarbonate
Study: NCT03143543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A Lorcaserin (10mg)
Description: 10 mg lorcaserin orally for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A2 Lorcaserin (20 mg)
Description: 20 mg lorcaserin orally for 7 days
Study: NCT02494830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
Study: NCT03143543

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B Parallel Placebo
Description: Oral placebo vs 10 mg lorcaserin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B2 Parallel Placebo
Description: Oral placebo vs 20 mg lorcaserin
Study: NCT00702689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec, STI571(Imatinib Mesylate)
Description: Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)
Study: NCT04504279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB-401
Description: Topical application
Study: NCT02494830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
Study: NCT02387346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation
Study: NCT04504279

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT01147588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole
Description: 60 mg (2x30-mg capsule), once daily
Study: NCT02387346

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Rapid 2 Sham Stimulation
Study: NCT02634008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir/ombitasvir
Study: NCT01147588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: 80 mg (2x40-mg capsule), once daily
Study: NCT02634008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Study: NCT01695343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB001-A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT01147588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40 mg (1x40-mg capsule), once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 300 mg loading dose on Day 1 then 75 mg daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 300 mg loading dose on Day 1 then 75 mg daily for 28 days
Study: NCT03129035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean hystrectomy
Description: Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean hystrectomy
Description: Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal iliac artery ligation
Description: The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
Study: NCT01124162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 100 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozaar®
Description: 100 mg Tablet
Study: NCT00762658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Ointment, 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Ointment, 2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Ointment, 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2728 Ointment Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betnesol®-V Creme, 0.1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic® Ointment, 0.1 %
Study: NCT00661752

Intervention type: DEVICE
Intervention: quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac
Description: Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
Study: NCT03539159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic conventional sized serum eye drops
Description: allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
Study: NCT03539159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic conventional sized serum eye drops
Description: allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic micro sized serum eye drops
Description: Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
Study: NCT01147588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 300 mg loading dose on Day 1 then 75 mg daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 300 mg loading dose on Day 1 then 75 mg daily for 28 days
Study: NCT03325088

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial endoscopy
Description: Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
Study: NCT03539159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic micro sized serum eye drops
Description: Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
Study: NCT02054247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ultrasound
Description: a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
Study: NCT03325088

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial biopsies
Description: 5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
Study: NCT02054247

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo ultrasound
Description: same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
Study: NCT03988387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support (PS)
Description: Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
Study: NCT03457662

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: OMC and SDT
Description: OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
Study: NCT03629717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided core needle biopsy
Description: Tissue collection for this research proposal will be used for research purposes only and will not inform participant care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: 20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 1200mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 800 IU daily
Study: NCT03211845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional telemonitoring
Description: Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
Study: NCT04428905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03325088

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial biopsies
Description: 5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial biopsies
Description: 5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial alveolar enema
Description: For participants who had signed ancillary research consent
Study: NCT03696043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axium Steatlh Image Guidance
Description: The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
Study: NCT03325088

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial alveolar enema
Description: For participants who had signed ancillary research consent
Study: NCT00645723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: intravenous colistin and nebulized colistin
Study: NCT00001168

Intervention type: BEHAVIORAL
Intervention: Balanced diet
Description: Dietary studies for the diagnosis of post-prandial hyperlipidemia will include a 3 week period while subjects are on a baseline, isoweight, 15% fat, 42% carbohydrate, normal polyunsaturated fat ratio (0.1-0.3) 250-300 mg cholesterol diet.